- Home
- AVIR vs GCO Comparison
AVIR vs GCO Comparison
Compare AVIR & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | GCO |
|---|---|---|
| Founded | 2012 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.0M | 286.0M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AVIR | GCO |
|---|---|---|
| Price | $6.08 | $25.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 569.0K | 229.5K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $351,367,000.00 | ★ $2,606,898,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $3.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.71 |
| 52 Week Low | $2.46 | $16.19 |
| 52 Week High | $6.45 | $38.95 |
Technical Indicators
Market Signals| Indicator | AVIR | GCO |
|---|---|---|
| Relative Strength Index (RSI) | 76.99 | 38.19 |
| Support Level | $3.33 | $21.57 |
| Resistance Level | N/A | $26.28 |
| Average True Range (ATR) | 0.31 | 1.79 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 79.43 | 10.90 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.